Netherlands· NL-cd89d6638ecc
Meropenem AptaPharma 2000 mg poeder voor oplossing voor infusie
A meropenem product containing meropenem 3-water, registered in Netherlands by Apta Medica Internacional d.o.o.. The same ATC class is registered in 18 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Meropenem is registered in 18 of 19 countries.
Countries holding a registration under ATC J01DH02 (meropenem), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Meropenem · ATC J01DH02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of meropenem costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Meropenem · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$99.79
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MEROPENEM 3-WATER
- Manufacturer
- Apta Medica Internacional d.o.o.
- Country
- Netherlands (NL)
- ATC code
- J01DH02
- ATC class
- Meropenem
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id133268
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
25 interactions on record for meropenem.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Meropenem · interactions on record
25 records
- 4 severe
- 20 moderate
Most severe, free to view
- BupropionN06AX12severe
- BupropionN07BA02severe
- IohexolV08AB02severe
- IopamidolV08AB04severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Meropenem in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMeropenemWG Critical Care, LLC
- CzechiaARCHIFARMedochemie Bohemia, spol. s r.o., Praha
- FinlandMerocarbAntibiotice SA
- SpainARCHIFAR 1G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFGMedochemie Iberia S.A.
- BelgiumMeronem IV 1 gPfizer
- SwedenMerocarb 1 g Pulver till injektions-/infusionsvätska, lösningAntibiotice SA
- United KingdomMeronem 1g powder for solution for injection vialsPfizer Ltd
- GermanyMeropenemHexal Ag
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Merinfec, Meropenem Aptapharma
- Belgium · Meronem Iv, Meropenem Bradex
- Bulgaria · Meropenem Kabi, Meropenem-Tchaikapharma
- Cyprus · Archifar, Meropenem Aptapharma
- Czechia · Archifar, Meronem
- Germany · Meropenem, Meropenem Acs Dobfar
- Denmark · Merocarb, Meropenem "thrive"
- Estonia · Agenor, Meropenem Bausch Health
- Spain · Archifar, Meropenem Aurovit
- Finland · Merocarb, Meropenem Aptapharma
- France · Meronem, Meropenem Acs Dobfar
- United Kingdom (Northern Ireland) · Meronem Iv, Meropenem
- Greece · Carbenem, Homepen
- Croatia · Archifar, Meropenem Aptapharma
- Hungary · Meropenem Aptapharma, Meropenem Bradex
- Ireland · Meronem I.V., Meropenem
- Iceland · Merinfec, Merocarb
- Italy · Luxomer, Meropenem Acs Dobfar
- Lithuania · Agenorem, Meropenem Kabi
- Luxembourg · Meronem Iv, Meropenem Bradex
- Latvia · Archifar, Meropenem Kabi
- Malta · Archifar, Mepenex
- Norway · Merocarb, Meropenem Aptapharma
- Poland · Meronem, Meropenem Aptapharma
- Portugal · Meropenem Atral, Meropenem Aurovitas
- Romania · Archifar, Loditer
- Sweden · Merocarb, Meronem
- Slovenia · Archifar, Meropenem Actavis
- Slovakia · Archifar, Merocarb
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f73939aa-a329-4a4c-bf6a-ba82adf4380b GET /v1/drugs/f73939aa-a329-4a4c-bf6a-ba82adf4380b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133268_smpc.pdf",
"strength": null,
"atc_label": "Meropenem",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133268",
"excipients": [
"NATRIUMCARBONAAT 0-WATER (E 500 (I))"
],
"substances": [
"MEROPENEM 3-WATER"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133268.pdf",
"authorised_at": "2024/09/18",
"procedure_number": "SI/H/0172/003",
"dispensing_status": "Uitsluitend recept",
"registration_number": "133268",
"additional_monitoring": "N"
}See everything about meropenem.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.